FLT3 inhibitor therapy was associated with the development of acute pericarditis in a 56-year-old man, which resolved rapidly upon drug discontinuation and anti-inflammatory treatment.
Case Report (n=1)
Does FLT3 inhibitor therapy cause acute pericarditis in patients with acute myeloid leukemia?
FLT3 inhibitors may cause acute pericarditis, highlighting the need for early recognition and drug withdrawal in affected patients.
BACKGROUND: FMS-like tyrosine kinase 3 (FLT3) inhibitors improve outcomes in acute myeloid leukemia cases but may cause cardiovascular toxicity. Inflammatory complications are rarely described. CASE SUMMARY: A 56-year-old man with FLT3-mutated acute myeloid leukemia developed acute pleuritic chest pain 3 days after the initiation of FLT3 inhibitor therapy. Electrocardiogram showed diffuse ST-segment elevation, and inflammatory markers were elevated (C-reactive protein 244 mg/L; normal <5 mg/L). Echocardiography revealed mild pericardial effusion. No viral prodrome or infectious cause was identified. Renal function and leukocyte count allowed standard therapy. The drug was discontinued, and treatment with ibuprofen and colchicine led to rapid resolution. DISCUSSION: FLT3 inhibitors have been associated with cardiotoxicity although pericardial inflammation is uncommon. This case supports a probable drug-related mechanism. TAKE-HOME MESSAGES: FLT3 inhibitors may cause acute pericarditis. Early recognition and drug withdrawal are essential for recovery.
Fernández et al. (Mon,) conducted a case report in FLT3-mutated acute myeloid leukemia (n=1). FLT3 inhibitor therapy was evaluated on Acute pericarditis. FLT3 inhibitor therapy was associated with the development of acute pericarditis in a 56-year-old man, which resolved rapidly upon drug discontinuation and anti-inflammatory treatment.